Mobile

A Phase IIa Multicenter, Randomized, Double-Blind, Placebo -Controlled, Parallel Group Study of RWJ-445380 Cathepsin-S Inhibitor in Patients with Active Rheumatoid Arthritis Despite Methotrexate Thera...

Update Il y a 4 ans
Reference: EUCTR2006-003983-73

A Phase IIa Multicenter, Randomized, Double-Blind, Placebo -Controlled, Parallel Group Study of RWJ-445380 Cathepsin-S Inhibitor in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To assess the safety and tolerability of RWJ-445380 at doses of 100, 200, or 300 mg/day for up to 12 weeks in patients with active Rheumatoid Arthritis (RA) despite methotrexate (MTX) therapy.

Inclusion criteria

  • Rheumatoid Arthritis

Links